Pharmaceutical Industry Reports Orexin Receptors | Page 2

REPORT DESCRIPTION
Orexin Receptors (Hypocretin Receptor) Antagonist Market – Overview
Orexin (hypocretin) is a neuropeptide produced by the lateral hypothalamus which regulates the wakefulness,
appetite, arousal and other habits. Orexin receptor antagonist is the new class of drugs are used in the treatment of
insomnia.
Suvorexant, is a dual orexin receptor antagonist drug that blocks both pathways of OX1R and OX2R. It develops
sleep by the binding inhibition of orexin A and B, neuropeptides that promote wakefulness. Approximately 70,000
orexin neurons are present in the human brain, located in the perifornical lateral hypothalamus, which send signals
throughout the brain and spinal cord.
The main growth driver for the Orexin receptors antagonist market is the rising cases of insomnia. Insomnia is
caused by plenty of reasons such as anxiety, stress and depression. Lifestyle problems can trigger insomnia like
irregular sleeping patters, drinking alcohol and smoking tobacco products before going to bed. Rising geriatric
population, increased stress levels in urban population also results into insomnia. According to American
Academy of Sleep Medicine AASM) as reported in 2014 insomnia affects 30% of adults, 15-20% have short term
insomnia and 10% of adults have chronic insomnia worldwide.